Personal Profile
Home → Directory → Faculty → Barbara Wirostko
Barbara  Wirostko

Barbara Wirostko

Clinical Adjunct Professor in Ophthalmology, Moran Eye Center
Adjunct Professor, Bioengineering
Invited Scientific Advisory Member for the Glaucoma foundation, NY, NY. 2013- present.
Invited speaker and moderator for the “New Horizons in Glaucoma Pharmaceuticals” session at the Glaucoma Research Foundation New Horizons meeting San Francisco, CA. Fe
Glaucoma Fellow, Cornell Medical Center NY, NY 1995-1996
Ophthalmology Residency, Columbia Presbyterian Medical Center NY 1992-1995
MD; Columbia University, College of Physicians & Surgeons, NY 1987-1991
BA with Distinction, Cornell U, 1987


Developing a biodegradable Hyaluronic acid polymer for use as an ocular therapy as well as an ophthalmic drug delivery device

Current Research

National Science Foundation, 4201 Wilson Blvd, Arlington, VA, 22230
Date submission/award: Phase II Submitted 1/2014. Awarded Nov 2014
Title: “A Hyaluronan-based Product for Ocular Delivery of Antibiotics.”
The objective is to continue the commercial development of a crosslinked HA polymer film to deliver topical ocular antibiotics. The work includes in vitro and in vivo work specific to antibiotic release testing, GMP manufacturing and tech transfer
Title/#/Solicitation Date: NSF SBIR-Phase II Solicitation FY-2013; 12-605 (BM3). Proposal # 1315150 $725,000 awarded
PI: Barbara Wirostko M.D. Jade CSO – Founder

Department of Defense, US Army US Army Research, Development and Engineering Command (RDECOM) 3071 Aberdeen Boulevard
Aberdeen Proving Ground, Maryland, 21005-5201
Date submission/award: Submitted June 2013. Awarded October 2013.
Title: “Novel hyaluronic acid delivery polymer for repair of ocular injuries”.
The objective is to develop a unique crosslinked hydrogel polymer delivery vehicle for the surface of the eye. The unique qualities of the HA hydrogel allow drugs and proteins to be delivered as well as HA itself for healing properties. Four variations of crosslinking films will be developed and in vitro & in vivo testing completed.
Title/#/Solicitation Date: DOD SBIR Phase 1; June 26, 2013. SBA SBC: SBC-000000884, Topic# A13-085: Proposal # A132-085-0022. $ 100,000 awarded with $50,000 contingent on Phase 2
PI: Barbara Wirostko M.D. Jade CSO

Selected Publications

Williams DL, Wirostko BM, Gum G, Mann BK, Topical Cross-Linked HA-Based Hydrogel Accelerates Closure of Corneal Epithelial Defects and Repair of Stromal Ulceration in Companion Animals. Invest Ophthalmol Vis Sci 2017 Sep 1;58(11):4616-4622

Aung T, Ozaki M, Lee MC, Schlötzer-Schrehardt U, Thorleifsson G, Mizoguchi T, Igo RP Jr, Haripriya A, Williams SE, Astakhov YS, Orr AC, Burdon KP, Nakano S, Mori K, Abu-Amero K, Hauser M, Li Z, Prakadeeswari G, Bailey JNC, Cherecheanu AP, Kang JH, Nelson , Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nat Genet 2017 Jul;49(7):993-1004

Aliancy J, Stamer WD, Wirostko B, A Review of Nitric Oxide for the Treatment of Glaucomatous Disease. Ophthalmol Ther 2017 Jun 5;:

Wirostko BM, Curtin K, Ritch R, Thomas S, Allen-Brady K, Smith KR, Hageman GS, Allingham RR, Risk for Exfoliation Syndrome in Women With Pelvic Organ Prolapse : A Utah Project on Exfoliation Syndrome (UPEXS) Study. JAMA Ophthalmol 2016 Nov 1;134(11):1255-1262

Morshedi RG, Ricca AM, Wirostko BM, Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide. J Glaucoma 2016 Mar;25(3):291-300

Wirostko B, Rafii M, Sullivan DA, Morelli J, Ding J, Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth Hormone. Ocul Surf 2015 Jul;13(3):204-212.e1

Ding J, Wirostko B, Sullivan DA, Human growth hormone promotes corneal epithelial cell migration in vitro. Cornea 2015 Jun;34(6):686-92

Wirostko B, Mann BK, Williams DL, Prestwich GD, Ophthalmic Uses of a Thiol-Modified Hyaluronan-Based Hydrogel. Adv Wound Care (New Rochelle) 2014 Nov 1;3(11):708-716

Maeda-Chubachi T, Chi-Burris K, Simons B, Brémond-Gignac D, Freedman S, Khaw PT, Wirostko B, Yan E, Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost. J Glaucoma 2013 Oct-Nov;22(8):614-9

Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM, Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther 2013 Mar;29(2):92-105

DeMill DL, Wirostko BM, Nelson LA, Stewart JA, Stewart WC, Average versus highest intraocular pressure analyses in glaucoma clinical trials. Ophthalmic Res 2013;49(1):49-51

Gooch N, Molokhia SA, Condie R, Burr RM, Archer B, Ambati BK, Wirostko B, Ocular drug delivery for glaucoma management. Pharmaceutics 2012 Mar 8;4(1):197-211

Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM, Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ 2012 Feb 21;344:e554

Poole-Wilson PA, Langer GA, Effect of pH on ionic exchange and function in rat and rabbit myocardium. Am J Physiol 1975 Sep;229(3):570-81